Advertisement
KALA vs OVID
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KALA is a Hold and OVID is a Hold.
Momentum Indicator for KALA turns negative, indicating new downward trend
KALA saw its Momentum Indicator move below the 0 level on September 24, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 74 similar instances where the indicator turned negative. In 71 of the 74 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for KALA turned negative on October 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 37 similar instances when the indicator turned negative. In 30 of the 37 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KALA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for KALA entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 13 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 17 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +11.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where KALA advanced for three days, in 167 of 208 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
KALA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 54 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.408) is normal, around the industry mean (2.988). P/E Ratio (-0.020) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. KALA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KALA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
OVID in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 13, 2026
OVID may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 36 of 38 cases where OVID's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where OVID's RSI Oscillator exited the oversold zone, 21 of 24 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 48 of 60 cases where OVID's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on OVID as a result. In 75 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for OVID just turned positive on October 21, 2026. Looking at past instances where OVID's MACD turned positive, the stock continued to rise in 41 of 54 cases over the following month. The odds of a continued upward trend are 76%.
Following a +13.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where OVID advanced for three days, in 207 of 269 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
Bearish Trend Analysis
OVID moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for OVID crossed bearishly below the 50-day moving average on September 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OVID declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for OVID entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.298) is normal, around the industry mean (2.988). P/E Ratio (-11.762) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.010) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (204.082) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 50 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. OVID’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OVID’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
KALA | OVID | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 53 | 30 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 54 Fair valued | 18 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 96 | |
PRICE GROWTH RATING 1..100 | 97 | 57 | |
P/E GROWTH RATING 1..100 | 6 | 50 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
OVID's Valuation (18) in the Pharmaceuticals Major industry is somewhat better than the same rating for KALA (54). This means that OVID’s stock grew somewhat faster than KALA’s over the last 12 months.
OVID's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as KALA (100). This means that OVID’s stock grew similarly to KALA’s over the last 12 months.
OVID's SMR Rating (96) in the Pharmaceuticals Major industry is in the same range as KALA (100). This means that OVID’s stock grew similarly to KALA’s over the last 12 months.
OVID's Price Growth Rating (57) in the Pharmaceuticals Major industry is somewhat better than the same rating for KALA (97). This means that OVID’s stock grew somewhat faster than KALA’s over the last 12 months.
KALA's P/E Growth Rating (6) in the Pharmaceuticals Major industry is somewhat better than the same rating for OVID (50). This means that KALA’s stock grew somewhat faster than OVID’s over the last 12 months.
| KALA | OVID | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 85% | 2 days ago 88% |
| Stochastic ODDS (%) | 2 days ago 77% | 2 days ago 80% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 80% |
| MACD ODDS (%) | 2 days ago 81% | 2 days ago 76% |
| TrendWeek ODDS (%) | 2 days ago 82% | 2 days ago 80% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 84% |
| Advances ODDS (%) | about 1 month ago 80% | 2 days ago 77% |
| Declines ODDS (%) | 9 days ago 90% | 10 days ago 85% |
| BollingerBands ODDS (%) | 2 days ago 85% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 87% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
KALA’s FA Score shows that 1 FA rating(s) are green while OVID’s FA Score has 1 green FA rating(s).
- KALA’s FA Score: 1 green, 4 red.
- OVID’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
KALA’s TA Score shows that 4 TA indicator(s) are bullish while OVID’s TA Score has 6 bullish TA indicator(s).
- KALA’s TA Score: 4 bullish, 4 bearish.
- OVID’s TA Score: 6 bullish, 4 bearish.
Price Growth
KALA (@Biotechnology) experienced а +1.49% price change this week, while OVID (@Biotechnology) price change was +12.79% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.02%. For the same industry, the average monthly price growth was -18.10%, and the average quarterly price growth was -15.28%.
Reported Earning Dates
KALA is expected to report earnings on Nov 18, 2026.
OVID is expected to report earnings on Nov 11, 2026.
Industries' Descriptions
@Biotechnology (-1.02% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
KALA and
Correlation & Price change
A.I.dvisor indicates that over the last year, KALA has been closely correlated with MLTX. These tickers have moved in lockstep 82% of the time. This A.I.-generated data suggests there is a high statistical probability that if KALA jumps, then MLTX could also see price increases.
| Ticker / NAME | Correlation To KALA | 1D Price Change % | ||
|---|---|---|---|---|
| KALA | 100% | +0.58% | ||
| MLTX - KALA | 82% Closely correlated | +3.20% | ||
| LRMR - KALA | 38% Loosely correlated | -0.82% | ||
| CLRB - KALA | 34% Loosely correlated | +4.07% | ||
| PALI - KALA | 31% Poorly correlated | -2.10% | ||
| OVID - KALA | 29% Poorly correlated | +4.66% | ||
More | ||||
OVID and
Correlation & Price change
A.I.dvisor indicates that over the last year, OVID has been loosely correlated with KURA. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if OVID jumps, then KURA could also see price increases.
| Ticker / NAME | Correlation To OVID | 1D Price Change % | ||
|---|---|---|---|---|
| OVID | 100% | +4.66% | ||
| KURA - OVID | 44% Loosely correlated | -1.00% | ||
| CLDX - OVID | 42% Loosely correlated | -3.04% | ||
| SANA - OVID | 40% Loosely correlated | -0.42% | ||
| SLDB - OVID | 39% Loosely correlated | +0.16% | ||
| EDIT - OVID | 39% Loosely correlated | -2.71% | ||
More | ||||